Advertisement

Naunyn-Schmiedeberg's Archives of Pharmacology

, Volume 391, Issue 9, pp 953–963 | Cite as

A population pharmacodynamic model characterizing neutropenia associated with pegylated interferon alpha 2-a therapy in patients with chronic hepatitis C viral infection

  • Mohammad I. Saleh
  • Nagham N. Hindi
Original Article

Abstract

Neutropenia is a hematologic disorder commonly reported in patients with chronic hepatitis C viral (HCV) infection. The objective of the present analysis is to describe the change in neutrophil count resulting from peglated interferon alpha 2-a (PEG-IFN α-2a) therapy in HCV-infected patients. A population pharmacodynamic model will be developed. We also plan to identify patient characteristics that contribute to the development of PEG-IFN α-2a-induced neutropenia in hepatitis C patients. A population pharmacodynamic modeling approach was applied to a cohort of patients (n = 292) with chronic HCV infection. Modeling was performed using NONMEM 6. Data was obtained from two phases III studies sponsored by Hoffmann-La Roche. Covariate screening was applied to evaluate various demographic and clinical characteristics as possible predictors of pharmacodynamic parameter during model development. A total of 4517 neutrophil counts from 292 subjects were analyzed by the proposed population pharmacodynamic model. A constant residual error model was used to the log-transformed neutrophil count. Platelet baseline count and uric acid level were identified as predictors of neutrophil pharmacodynamic model. Increased baseline platelet count is expected to result in higher neutrophil baseline. A higher neutrophil baseline is also expected in patients with increased uric acid level. In conclusion, a mechanistic pharmacodynamic model was developed. The effect of various covariates was included in the model. This allows the prediction of neutrophil count following antiviral therapy in patients with hepatitis C infection. Clinical studies: NV15942 and NV15801

Keywords

Neutropenia Hepatitis C NONMEM Pharmacodynamic Neutrophil Model 

Notes

Acknowledgments

All authors approved the final version of the article, including the authorship list.

Author contribution statement

MS and NH conceived and designed research. MS developed NONMEM code and designed modeling experiment. NH analyzed data. MS and NH wrote the manuscript. All authors read and approved the manuscript.

Funding

No funding has been received for the conduct of this study and/or preparation of this manuscript.

Compliance with ethical standards

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. Alter MJ, Mast EE (1994) The epidemiology of viral hepatitis in the United States. Gastroenterol Clin N Am 23:437–455Google Scholar
  2. Alzubiedi S, Saleh MI (2017) Predictors of severe thrombocytopenia secondary to peginterferon alfa-2a treatment in subjects with hepatitis C virus infection. Am J Ther 24(6):e670–e675Google Scholar
  3. Bekkering FC, Neumann AU, Brouwer JT, Levi-Drummer RS, Schalm SW (2001) Changes in anti-viral effectiveness of interferon after dose reduction in chronic hepatitis C patients: a case control study. BMC Gastroenterol 1:14CrossRefPubMedPubMedCentralGoogle Scholar
  4. Camma C, Giunta M, Andreone P, Craxi A (2001) Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 34:593–602CrossRefPubMedGoogle Scholar
  5. Dancey JT, Deubelbeiss KA, Harker LA, Finch CA (1976) Neutrophil kinetics in man. J Clin Invest 58:705–715CrossRefPubMedPubMedCentralGoogle Scholar
  6. Fischbach F, Fischbach FT, Dunning MB (2014) A manual of laboratory and diagnostic tests. Wolters Kluwer Health, PhiladelphiaGoogle Scholar
  7. Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO (2002) Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol Off J Am Soc Clin Oncol 20:4713–4721CrossRefGoogle Scholar
  8. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975–982CrossRefPubMedGoogle Scholar
  9. Juarez-Navarro A, Vera-de-Leon L, Navarro J, Chirino-Sprung R, Diaz-Hernandez M, Casillas-Davila L, Dehesa-Violante M (2005) Incidence and severity of infections according to the development of neutropenia during combined therapy with pegylated interferon-a2a plus ribavirin in chronic hepatitis C infection. Methods Find Exp Clin Pharmacol 27:317–322CrossRefPubMedGoogle Scholar
  10. Lavanchy D (2011) Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 17:107–115CrossRefPubMedGoogle Scholar
  11. Nachnani JS, Rao GA, Bulchandani D, Pandya PK, Alba LM (2010) Predictors of hematological abnormalities in patients with chronic hepatitis C treated with interferon and ribavirin. Ann Hematol 89:121–125CrossRefPubMedGoogle Scholar
  12. Pillay J, den Braber I, Vrisekoop N, Kwast LM, de Boer RJ, Borghans JA, Tesselaar K, Koenderman L (2010) In vivo labeling with 2H2O reveals a human neutrophil lifespan of 5.4 days. Blood 116:625–627CrossRefPubMedGoogle Scholar
  13. Ruggiero C, Cherubini A, Ble A, Bos AJ, Maggio M, Dixit VD, Lauretani F, Bandinelli S, Senin U, Ferrucci L (2006) Uric acid and inflammatory markers. Eur Heart J 27:1174–1181CrossRefPubMedPubMedCentralGoogle Scholar
  14. Russo F, Bacosi M, Miglioresi L, Ricci GL (2000) Leucopenia is a side effect of combination therapy for hepatitis C infection. Am J Gastroenterol 95:1100–1101CrossRefPubMedGoogle Scholar
  15. Saleh M (2014) Predictors of long term opioid withdrawal outcome after short-term stabilization with buprenorphine. Eur Rev Med Pharmacol Sci 18:3935–3942PubMedGoogle Scholar
  16. Saleh MI (2016) Clinical predictors associated with warfarin sensitivity. Am J Ther 23:e1690–e1694CrossRefPubMedGoogle Scholar
  17. Saleh MI (2017) A Bayesian approach for population pharmacokinetic modeling of Pegylated interferon α-2a in hepatitis C patients. Clin Pharmacokinet 56(11):1396–1379Google Scholar
  18. Saleh MI, Obeidat AR, Anter HA, Khanfar AA (2015) Eltrombopag dose predictors in thrombocytopenic subjects with hepatitis C virus infection. Clin Exp Pharmacol Physiol 42:1030–1035CrossRefPubMedGoogle Scholar
  19. Sheehan V, Weir A, Waters B (2013) Severe neutropenia in patients with chronic hepatitis C: a benign condition. Acta Haematol 129:96–100CrossRefPubMedGoogle Scholar
  20. Sheehan VA, Weir A, Waters B (2014) Hepatitis C and neutropenia. Curr Opin Hematol 21:58–63CrossRefPubMedGoogle Scholar
  21. Soto E, Staab A, Tillmann C, Trommeshauser D, Fritsch H, Munzert G, Troconiz IF (2010) Semi-mechanistic population pharmacokinetic/pharmacodynamic model for neutropenia following therapy with the Plk-1 inhibitor BI 2536 and its application in clinical development. Cancer Chemother Pharmacol 66:785–795CrossRefPubMedGoogle Scholar
  22. Stroup TS, Lieberman JA (2010) Antipsychotic trials in schizophrenia: the CATIE project. Cambridge University Press, CambridgeCrossRefGoogle Scholar
  23. Takama H, Tanaka H, Nakashima D, Ueda R, Takaue Y (2006) Population pharmacokinetics of intravenous busulfan in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 37:345–351CrossRefPubMedGoogle Scholar
  24. Wang B, Ludden TM, Cheung EN, Schwab GG, Roskos LK (2001) Population pharmacokinetic-pharmacodynamic modeling of filgrastim (r-metHuG-CSF) in healthy volunteers. J Pharmacokinet Pharmacodyn 28:321–342CrossRefPubMedGoogle Scholar
  25. Wang X, Gao F, Yuan G, Shi K, Huang Y, Chen Y, Qiu R, Sun L, Liu J, Hu C, Zhou Y (2016) Ten-year follow-up analysis of chronic hepatitis C patients after getting sustained virological response to pegylated interferon-alpha and ribavirin therapy. J Viral Hepat 23(12):971–976CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.School of PharmacyThe University of JordanAmmanJordan

Personalised recommendations